BR0210907A - Vetores de flavivìrus quiméricos - Google Patents

Vetores de flavivìrus quiméricos

Info

Publication number
BR0210907A
BR0210907A BR0210907-7A BR0210907A BR0210907A BR 0210907 A BR0210907 A BR 0210907A BR 0210907 A BR0210907 A BR 0210907A BR 0210907 A BR0210907 A BR 0210907A
Authority
BR
Brazil
Prior art keywords
vectors
chimeric flavivirus
flavivirus vectors
flavivers
employing
Prior art date
Application number
BR0210907-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Harold Kleanthous
Larisa Oros
Charles Miller
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of BR0210907A publication Critical patent/BR0210907A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR0210907-7A 2001-06-01 2002-05-31 Vetores de flavivìrus quiméricos BR0210907A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29526501P 2001-06-01 2001-06-01
PCT/US2002/017374 WO2002102828A2 (en) 2001-06-01 2002-05-31 Chimeric flavivirus vectors

Publications (1)

Publication Number Publication Date
BR0210907A true BR0210907A (pt) 2004-12-21

Family

ID=23136958

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210907-7A BR0210907A (pt) 2001-06-01 2002-05-31 Vetores de flavivìrus quiméricos

Country Status (11)

Country Link
US (2) US7569383B2 (enExample)
EP (1) EP1401859B1 (enExample)
JP (1) JP2005501532A (enExample)
KR (1) KR100921592B1 (enExample)
CN (1) CN1551782A (enExample)
AU (1) AU2002322026B2 (enExample)
BR (1) BR0210907A (enExample)
CA (1) CA2448971C (enExample)
ES (1) ES2439724T3 (enExample)
PL (1) PL371187A1 (enExample)
WO (1) WO2002102828A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
AU2003290985B2 (en) 2002-11-15 2010-04-01 Acambis Inc. West nile virus vaccine
RU2009105099A (ru) * 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
KR20090096414A (ko) * 2006-09-29 2009-09-10 사노피 파스테르 바이오로직스 씨오 재조합 리노바이러스 벡터
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
CA2668834C (en) 2006-11-07 2016-10-11 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
EP2117589A4 (en) * 2007-01-31 2010-07-21 Sanofi Pasteur Biologics Co FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
JP5779352B2 (ja) 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
JP2011517408A (ja) * 2008-03-27 2011-06-09 サノフィ パスツール バイオロジクス カンパニー 組換えライノウイルスベクター
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2408477A4 (en) * 2009-03-16 2013-03-27 Sanofi Pasteur Biologics Llc REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
BR112014009887A2 (pt) * 2011-10-25 2017-04-25 Florida Gulf Coast Univ vacinmas e métodos para desenvolvimento de vacina para indução de imunidade a todos os sorotipos de virus da dengue
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CA2878599A1 (en) * 2012-07-24 2014-01-30 Jiansheng Yao Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
US10428313B2 (en) 2014-06-20 2019-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric West Nile/Dengue viruses and methods of use
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
BR112019019813A2 (pt) 2017-03-30 2020-04-22 The University Of Queensland moléculas quiméricas e usos das mesmas
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
AU2018346724B2 (en) 2017-10-05 2025-01-09 Sanofi Pasteur Compositions for booster vaccination against dengue
US20220168412A1 (en) * 2019-04-10 2022-06-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese Encephalitis Virus
CN111798712B (zh) * 2020-07-15 2021-10-29 周晓庆 噬菌体侵染细菌3d智能模拟方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
DE69230316T2 (de) 1991-09-19 2000-07-13 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
CA2282790C (en) 1997-02-28 2011-04-19 St. Louis University Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6416783B1 (en) * 1999-08-20 2002-07-09 Wisconsin Alumni Research Foundation Aspartic and malic acid inhibition of ss-glucuronidase
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
US6682883B1 (en) 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
DK1441761T3 (da) 2001-10-19 2007-08-27 Acambis Inc Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
AU2003290985B2 (en) 2002-11-15 2010-04-01 Acambis Inc. West nile virus vaccine
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (en) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
CN103031279B (zh) 2005-04-24 2015-11-18 赛诺菲巴斯德生物制药有限责任公司 重组黄病毒疫苗
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Also Published As

Publication number Publication date
CA2448971A1 (en) 2002-12-27
WO2002102828A3 (en) 2003-10-09
EP1401859B1 (en) 2013-08-07
KR20040003043A (ko) 2004-01-07
ES2439724T3 (es) 2014-01-24
PL371187A1 (en) 2005-06-13
US20110014229A1 (en) 2011-01-20
CA2448971C (en) 2013-11-26
US20030044773A1 (en) 2003-03-06
AU2002322026B2 (en) 2008-03-13
JP2005501532A (ja) 2005-01-20
WO2002102828A2 (en) 2002-12-27
US7569383B2 (en) 2009-08-04
EP1401859A4 (en) 2004-12-29
KR100921592B1 (ko) 2009-10-14
EP1401859A2 (en) 2004-03-31
CN1551782A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
WO2002102828A3 (en) Chimeric flavivirus vectors
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
DE69910580D1 (de) Von der telomerase abgeleitete antigene peptide
EP1371664A4 (en) WTI-MODIFIED PEPTIDE
ATE375365T1 (de) Antikörper varianten und fragmente davon
ATE182791T1 (de) Wiederhergestellte influenza-virosomen mit immunostimulierenden und immunoverstärkenden eigenschaften und diese enthaltende impfstoffe
DE60032367D1 (de) Aktivierbare rekombinante neurotoxine
MXPA03010103A (es) Peptidos y composiciones anti-microbianos.
ATE368053T1 (de) Antimikrobielle peptide
IS5887A (is) Interferón-beta bræðsluprótín og notkun þeirra
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ATE412004T1 (de) Transfektions-komplexe
GB0113798D0 (en) Antigens and vectors for vaccination
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
ATE356140T1 (de) Gd3 mimetische peptide
ATE469655T1 (de) Bakteriophagenvermittelte impfung
WO2002077241A3 (en) Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002070665A8 (en) Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
AU8542701A (en) Stress proteins and peptides and methods of use thereof
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
DE60236330D1 (de) Biologisch aktive Peptide
DE69903553D1 (de) Verkapselung wasserlöslicher peptide
MXPA03008438A (es) Toxina insecticida de bacillus thuringiensis modificada sensible a pepsina.
MXPA02012030A (es) Sustratos peptidicos de metalorpoteasas y metodos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.